The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review
| Autor: | Erika Meaddough, Tracy Fasolino, Christopher L. Farrell, Sara M. Sarasua |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pharmacology Polypharmacy medicine.medical_specialty business.industry Treatment adherence Disease Health outcomes 030226 pharmacology & pharmacy Clinical decision support system 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Genetics Molecular Medicine Medicine In patient business Intensive care medicine Pharmacogenetics ADME |
| Zdroj: | The Pharmacogenomics Journal. 21:409-422 |
| ISSN: | 1473-1150 1470-269X |
| Popis: | Polypharmacy poses a significant risk for adverse reactions. While there are clinical decision support tools to assist clinicians in medication management, pharmacogenetic testing to identify potential drug-gene or drug-drug-gene interactions is not widely implemented in the clinical setting. A PRISMA-compliant scoping review was performed to determine if pharmacogenetic testing for absorption, distribution, metabolism, and excretion (ADME)-related genetic variants is associated with improved clinical outcomes in patients with polypharmacy. Six studies were reviewed. Five reported improved clinical outcomes, reduced side effects, reduction in the number of drugs used, or reduced healthcare utilization. The reviewed studies varied in methodological quality, risk of bias, and outcome measures. Age, diet, disease state, and treatment adherence also influence drug response, and may confound the relationship between genetic polymorphisms and treatment outcomes. Further studies using a randomized control design are needed. We conclude that pharmacogenetic testing represents an opportunity to improve health outcomes in patients exposed to polypharmacy, particularly in patients with psychiatric disorders and the elderly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink